https://orcid.org/0000-0002-7966-0110
Figures
Abstract
Background
Envenoming by Bothrops lanceolatus, a viperid endemic to Martinique an island in the Lesser Antilles, induces a unique clinical manifestation, i.e., thrombosis. Pathophysiological signaling leading to thrombotic events remains poorly understood. Among others, proposed mechanisms include increased expression of multimerized forms of von Willebrand factor (VWF). Prothrombotic effects of VWF are regulated by ADAMTS13, a metalloprotease which cleaves VWF multimers. Whether ADAMTS13 activity is reduced in B. lanceolatus envenoming has not been previously investigated.
Methodology/Principal Findings
ADAMTS13 activity was evaluated via chromogenic assay in experimental and clinical studies. Human plasma with known ADAMTS13 activities (0.70 IU/mL) was incubated with increasing doses of B. lanceolatus venom. Incubation with B. lanceolatus venom (concentrations 10–1000 ng/mL) induced a dose-dependent reduction of ADAMTS13 activity. In our series of 46 patients bitten by B. lanceolatus snake, ADAMTS13 activity was determined at admission before antivenom therapy. In these patients, the median plasmatic ADAMTS13 activity was 94% (IQR: 78–122%). Ten patients (22%) displayed ADAMTS13 activity less than 75%. Compared with patients with normal ADAMTS13 activity (n = 36), those with moderately low ADAMTS13 activity (n = 10) were older, had a lower platelet count, and displayed increased concentrations of creatine kinase, fibrinogen and C-reactive protein. Multivariate linear regression retained only grade severity of envenoming as independent predictor of increase length of hospital stay, while reduced ADAMTS13 activity and increased C-reactive protein levels bordered on statistical significance.
Conclusions/Significance
For the first time, our study provided evidence suggesting that ADAMTS13 activity is reduced in experimental B. lanceolatus venom exposure and patients with B. lanceolatus envenoming. Thanks to its role on the VWF regulation, it is suggested that reduced ADAMTS13 activity can increase the risk of thrombosis in B. lanceolatus envenoming by favoring the circulation of prothrombotic VWF multimers. Low ADAMTS13 activity was associated with increased length of stay in envenomed patients.
Author summary
The clinical manifestations of envenoming by Bothrops sp. typically include local tissue injury and disturbances of hemostasis characterized by consumption coagulopathy leading to incoagulable blood. In contrast, B. lanceolatus envenoming can elicit thrombotic events, such as ischemic stroke and myocardial infarction. Proposed mechanisms include the combination of procoagulant and systemic inflammatory processes leading to thrombotic state. The factor von Willebrand (VWF) is an active biomolecule critical for coagulation and thrombosis processes. The amount of multimerized forms of VWF increases the risk of thrombosis. VWF is regulated by ADAMTS13, an enzyme that cleaves VWF multimers and reduced their prothrombotic effects. Whether ADAMTS13 activity is reduced in B. lanceolatus envenoming has not been previously investigated, while only few case reports have previously evaluated the levels of ADAMTS13 activity in human envenoming. For the first time in this study, we study provided evidence suggesting that ADAMTS13 activity is reduced in experimental B. lanceolatus venom exposure and in human B. lanceolatus envenoming. Our study results further suggest that, together with high grade severity score of envenoming and systemic inflammation, moderately reduced levels of ADAMTS13 activity are associated with increased length of hospital stays.
Citation: Florentin J, Rapon C, Pierre-Louis O, Radouani F, Jalta P, Fuseau P, et al. (2025) ADAMTS13 in Bothrops lanceolatus snakebite envenoming: Crude venom-induced reduction of in vitro enzymatic activity and clinical correlation in snakebite patients. PLoS Negl Trop Dis 19(10): e0013678. https://doi.org/10.1371/journal.pntd.0013678
Editor: Wuelton Monteiro, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado: Fundacao de Medicina Tropical Doutor Heitor Vieira Dourado, BRAZIL
Received: August 29, 2025; Accepted: October 22, 2025; Published: October 29, 2025
Copyright: © 2025 Florentin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: Data are included in Supporting Information files of the submitted manuscript.
Funding: This work was supported by APIDOM GIRCI SOHO - Direction Générale de l’Offre de Soins (WBOTHROPS 2019 to RN) - URL: https://www.girci-soho.fr/ and ANR Agence Nationale de la Recherche (AAPG 2025 - PRC – KariBothrops to DR) - URL: https://anr.fr/ The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
The clinical manifestations of envenoming by Bothrops sp. include local effects, such as pain, edema, and necrosis, and systemic complications, such as disturbances of hemostasis characterized by consumption coagulopathy and defibrinogenation, and, in some cases, acute kidney failure and circulatory shock [1–3]. In contrast to the typical hemostatic alterations induced by Bothrops sp. venoms, envenoming by B. lanceolatus can elicit diffuse thrombotic microangiopathy and severe thrombotic events within 48h of the bite [4–6].
B. lanceolatus is a viperid species endemic to Martinique, an island in the Lesser Antilles of the West Indies in the south of the Caribbean Sea. Before the era of immunotherapy, B. lanceolatus envenoming was associated with systemic arterial thrombotic complications leading to cerebral, myocardial or pulmonary infarctions in 25–30% of cases and was fatal in about 10% of cases [7–11]. Since the mid 1990s, the use of the monospecific antivenom Bothrofav (Micropharm, UK), has reduced mortality to zero and prevented most of the thrombosis complications [7–11]. Despite excellent efficiency of Bothrofav, the exact pathophysiological mechanisms leading to B. lanceolatus venom-induced thrombotic complications remain poorly understood. In absence of overt proaggregating or procoagulant activities, proposed mechanisms of B. lanceolatus venom-induced thrombosis include increased expression of tissue factor, complement system activation, endothelial dysfunction and immune inflammatory systemic response [10,12–14].
Biological features consistent with thrombotic microangiopathy has been described after snakebite for many years [15,16]. In viperid envenoming, thrombotic microangiopathy has been previously described in some Bothrops sp. envenoming, including by B. jararaca, B. venezuelensis and B. erythromelas [17–19]. In these cases, patients presented on admission a typical local bothropic syndrome with no signs of systemic bleeding, whereas thrombotic microangiopathy can developed within the few days after snakebite [15–19]. Of note, thrombotic microangiopathy is the overarching term used to describe any disease process characterized by thrombocytopenia and microangiopathic hemolytic anemia with or without other clinical or laboratory features (thrombocytopenia, hemolytic anemia with presence of schistocytes in blood smears, decreased haptoglobin level, increased lactate dehydrogenase level and acute kidney injury) [20,21]. Primary thrombotic microangiopathies include hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP). Typical TTP is broadly defined as a thrombotic microangiopathy occurring in the context of severe ADAMTS13 deficiency (<10%), while ADAMTS13 is usually not decreased in HUS [20–22]. Secondary forms of thrombotic microangiopathies, which occur in the context of pregnancy, autoimmune disease, malignancy, bone marrow transplantation or use of certain medications, are associated with mildly reduced or even normal ADAMTS13 activity [21–23].
ADAMTS13 is a disintegrin-like and metalloproteinase with a thrombospondin type 1 motif, member 13, which regulates hemostasis and thrombosis processes related to von Willebrand factor (VWF) pathway. VWF activity is regulated by ADAMTS13, an enzyme that cleaves VWF multimers and reduced their prothrombotic effects [23]. Increasing evidence suggest that even moderate decreases of ADAMTS13 activity can also predispose to ischemic cardiovascular diseases, particularly myocardial infarction and ischemic stroke [24,25]. Previous experimental reports in Bothrops sp. envenoming have described mild reduction of ADAMTS13 activity [26,27]. In B. jararaca envenoming, reduction of ADAMTS13 was associated with reduced VWF levels and cleavage of high molecular weight VWF multimers [26]. B. jararaca venom was also shown to downregulate mRNA synthesis of hepatic Adamts13 [28]. In human envenoming, only few case reports have previously evaluated the levels of ADAMTS13 activity, which were normal when tested [17,18,29–31].
Whether reduced ADAMTS13 activity would play a role in the endothelial dysfunction and risk of thrombosis associated with B. lanceolatus envenoming have not been studied. We hypothesized that moderately reduced levels of ADAMTS13 activity may be involved in the pathophysiological mechanisms of the thrombotic complications associated with B. lanceolatus envenoming. Primary objectives of our study were to test whether plasmatic ADAMTS13 activity would be reduced by in vitro exposure to B. lanceolatus venom and in humans bitten by B. lanceolatus snake. Secondary objective of the study was to test the clinical relevancy of low ADAMTS13 levels in patients bitten by B. lanceolatus snake.
Patients and methods
Ethics statement
The study was approved by the CHU Martinique hospital’s institutional review board (IRB #01072019). Patients were managed in accordance with the amended Declaration of Helsinki (http://www.wma.net/ en/30publications/10policies/b3/). Patients were informed that their clinical and laboratory results may be used for research purposes. This consent was recorded in the patient’s electronic medical record. Due to the retrospective nature of this study and anonymous analysis of patient records, the exemption of written informed consent was approved by the IRB of CHU Martinique.
Venom and antivenom
Crude venom was obtained from 6 adult females and 6 males (112–156 cm long) caught in the wild in various locations of Martinique. Median (25th-75th percentiles) length of snakes was 168 (150–172) cm in female specimens and 158 (123–166) cm in male specimens. Venom samples were pooled, lyophilized (Freezone, Labconco, Kansas City, MO, USA) and stored at -80°C until use (stock solution 10 mg/mL). In in vitro experiments, B. lanceolatus venom was used at final concentrations ranging from 10 to 1000 ng/mL.
Bothrofav (Micropharm, UK), a preparation containing F(ab’)2 fragments that have the property of neutralizing B. lanceolatus venom, was administered in clinical B. lanceolatus envenoming. These equine F(ab’)2 fragments ligate venom antigens present in circulating blood to form inactive F(ab’)2-antigen complexes, in turn reducing the amount of free venom in circulation. Bothrofav was used (batch J8216; protein concentration of 20.7 ± 0.05 g/dL) at the final concentrations of 0.21 mg/mL.
Assay of ADAMTS13 activity in in vitro plasmatic preparation
Chromogenic assay of ADAMTS13 activity was performed in human plasma prepared from lyophilized standard control plasma as advised by the supplier (control N 5020050, Technozym, Cryopep, France) and a commercial ELISA kit for ADAMTS13 activity (Reference 4–5450701, Technozym, Cryopep, France). The plate was incubated with GST-VWF for 1 hour and then washed three times, in accordance with the manufacturer’s instructions. The samples were then incubated in the wells for 30 minutes, followed by three other washes. The plate was then incubated with the HRP-conjugated anti-VWF antibody for 1 hour and washed three times. Finally, the plate was incubated with the chromogenic substrate for 30 min and an acetic acid solution was added rapidly to stop the reaction. Absorbance was measured within 10 minutes. The optical density reading was obtained using a spectrophotometer at 450 nm (AMR-100, Allsheng, Hangzhou, China).
Assay of ADAMTS13 activity in envenomed patients
Venous blood was collected into 5-mL blue-top tubes (3.2% sodium citrate) and kept at 4° C for less than 24 hours. Anticoagulated blood was centrifuged at 1100g for 10 minutes, and plasma was stored at -70° C until assay. Levels of ADAMTS13 activity were measured via a chromogenic ADAMTS13 activity ELISA kit (Reference 4–5450701, Technozym, Cryopep, France). The principle of the assay is related to the incubation of plasma with a fragment of VWF (GST-vWF73 substrate). The specific cleavage of this fragment by ADAMTS13 is then detected using a labeled antibody targeting the cleaved VWF fragment. The intensity of the staining is directly proportional to the amount of cleaved substrate and, therefore, to the ADAMTS13 activity in the plasma sample. According to manufacturer’s instructions, incubation times for the GST-vWF73 substrate and study sample were 60 min and 30 min, respectively. Incubation times for the conjugated antibody and chromogenic substrate were 60 min and 30 min, respectively. The reaction was stopped and optical density was measured at 450 nm. Calibrators from 0 to 1 IU/mL (Cal Set 4–5450761, Technozym) and controls (Control Set 4–5450763, Technozym) of 0.70 IU/mL concentration were used for the determination of ADAMTS13 activity. Controls and calibrators have been calibrated against the 1st WHO international standard (NIBSC code 12/252) in IU/mL. Activity of ADAMTS13 was expressed as percent of controls.
Patients
Patients with the diagnosis of B. lanceolatus envenoming presenting at the University Hospital of Martinique from January 2019 to January 2023 were retrospectively included in the study. Information regarding the possible use of the clinical records for research was provided to patients at time of hospitalization and consent was written in the medical file of the patient. All patients were managed in accordance with the amended Declaration of Helsinki (http://www.wma.net/en/30publications/10policies/b3/). The study was approved by the CHU Martinique hospital’s institutional review board (IRB #01072019).
Diagnosis and antivenom therapy of B. lanceolatus snakebite envenoming
When seen, the culprit snake was identified based on the patient’s description, photographs, or the physical examination of the captured snake. Snakebite was confirmed by the observation of two puncture wounds resulting from snake fang marks. Patient health data were collected using the Emergency DX Care software (Medasys, Dedalus, France) on hospital presentation. Data recording and patient management was performed with the help of dedicated senior toxicologist physicians of the snakebite team at the CHU Martinique. Clinical data, including age and gender of patients, date and time of the bite, anatomical site of the bite, grade of severity of envenoming, clinical manifestations and routine biological tests at admission, date and time of hospital admission, and antivenom administration were collected from the DX Care medical record of the patients. For ADAMTS13 activity assay, peripheral whole blood was collected with sodium citrate at admission All samples were stored at −80 °C, thawed at 37 °C immediately before testing, and were not refrozen. The severity of envenoming of each patient was measured according to a previously defined clinical severity scale. Development of envenoming, occurrence of adverse events, duration of hospital stays, and outcome were monitored for each patient. We excluded patients hospitalized for snakebite envenoming lasting more than 48 hours after the bite and those who did not present clinical or biological signs of envenoming. Envenomed patients were treated by intravenous infusion of antivenom Bothrofav at dose adjusted to the severity grade of the case.
Statistical analysis
Quantitative data were presented as mean ± standard deviation (SD) or median IQR. The Shapiro-Wilk test was used to test for normal distribution of quantitative data. Median, interquartile range, and minimum–maximum ranges are described for non-normally distributed variables. Categorical data are presented as absolute values with percentages. The following tests were used for group comparisons: Student’s t-test, analysis of variance ANOVA, chi-square test, and Fisher’s exact test. When a significant difference was found, we identified specific differences between groups with a sequentially rejective Bonferroni procedure. Level of statistical significance was set at p < 0.05. In this exploratory work, univariate and multivariate linear regression models were implemented to assess the independent effect of potential predictors of length of hospital stay in the study population. All statistical analyses were conducted using IBM SPSS Statistics version 27 for Windows software. Figures were processed using Prism 6 for Windows software (Graphpad, Boston MA, USA).
Results
In vitro effects of B. lanceolatus venom on ADAMTS13 activity in plasmatic samples prepared from commercialized control human plasma
Venom incubation with plasma samples displaying a fixed ADAMTS13 activity induced optical density changes of the plasma staining, which is directly proportional to the amount of cleaved chromogenic substrate and, therefore, the ADAMTS13 activity in the sample. Incubation of plasma displaying known ADAMTS13 activities (0.70 IU/mL) with B. lanceolatus venom induced a dose dependent (1–1000 ng/mL) reduction of ADAMTS13 activity (Fig 1).
Experiments were performed with B. lanceolatus venom concentrations ranging from 10 to 1000 ng/mL. Results are displayed as box plot with median, min to max data points. N=5-6 experiments, *** indicates p<0.01, **** indicates p<0.001.
Main characteristics and ADAMTS13 activity in human B. lanceolatus envenoming
From January 2019 to January 2023, a total of 116 patients suffering envenoming by B. lanceolatus were included in the study. Patient health data was carefully collected using the Emergency DX Care software (Medasys, Dedalus, France) on hospital presentation. Patient’s registry, critical information such as clinical and biological presentation, envenoming grade severity, timing of antivenom administration, antivenom protocol, thrombotic complications and follow-up were fully available (Table 1). Among the 116 envenomed patients, a total of 46 patients (39.6%) had have ADAMTS13 activity determination at admission before antivenom therapy. There were no differences in terms of clinical conditions, main snakebite characteristics and grade severity between patients who had or not ADAMTS13 activity determination (Table 1).
Main characteristics of the 46 patients with available ADAMTS13 activity determination are displayed Table 2.
The median age of these 46 patients was 49 years (IQR: 36–60). The median time from the snakebite to hospital admission was 2:17 hours (IQR: 1:51–3:30). Most participants were male (70%). The envenomed patients were agricultural workers in 30% of cases. Moderate envenoming was the most common presentation (78%). Two patients developed ischemic cerebral stroke. The median plasmatic ADAMTS13 activity was 94% (IQR: 78–122%), while an ADAMTS13 activity less than 75% was observed in ten (22%) patients. This group of 10 patients were older and displayed a lower platelet count (which remain normal), a more intense myonecrosis along with higher fibrinogen and C-reactive protein levels compared with patients with normal ADAMTS13 activity (Table 2).
Levels of main biological parameters of the 46 patients according to age of the patients are displayed S1 Table. No statistical differences were found between patients >65-year-old compared with patients <65-year-old).
Due to the small number of cerebral strokes in our series (n = 2 patients), the clinical relevancy of low ADAMTS13 levels as an independent factor of thrombotic complications was not investigated. While low ADAMTS13 levels has been consistently associated with end-organ failure, longer hospital stays and increased mortality in various pathologies, we further tested whether ADAMTS13 level as an independent predictor of length of hospitalized patients suffering B. lanceolatus envenoming. In line, a multivariate linear regression was performed to test the relationship between length of hospital stay and independent predictors (Table 3).
Variables were considered for multivariate analysis after taking into account their clinical pertinence and significant association (p < 0.10) in univariate analysis. Variables entered into the initial multivariate linear model for length of hospital stay: age, grade of the envenoming, fibrinogen, CPK, C-reactive protein and ADAMTS13 activity. A backward stepwise regression approach was then applied to produce the final multivariate model, with a statistical significance level set at p < 0.05. Multivariate linear regression retained only grade severity of envenoming as independent predictor of increase length of hospital stay, while reduced ADAMTS13 activity and increased C-reactive protein levels bordered on statistical significance.
Discussion
A syndrome consistent with thrombotic microangiopathy may develop within the few days after snakebite envenoming and combines features such as thrombocytopenia, hemolytic anemia with presence of schistocytes in blood smears, decreased haptoglobin level, increased lactate dehydrogenase level and acute kidney injury [15,16]. While thrombotic microangiopathy has been occasionally described in Bothrops sp. envenoming [17–19,29–32], only few case reports have previously evaluated the levels of ADAMTS13 [17,18,29–31], the main biological factor of endothelial dysfunction and thrombosis risk associated with this syndrome. For the first time, our study provided evidence suggesting that ADAMTS13 activity is reduced in experimental venom exposure and in human B. lanceolatus envenoming. While it was found that reduced ADAMTS13 activity <75% was not associated with more severe envenoming, our study results further suggest that, together with high grade severity score of envenoming and increased C-reactive protein, moderately reduced levels of ADAMTS13 activity are associated with increased length of hospital stays.
ADAMTS13 is primarily synthesized in the liver, and its main function is to cleave von Willebrand factor (VWF) anchored on the endothelial surface, in circulation, and at the sites of vascular injury [20–23]. The formation and elongation of VWF strings on endothelial surfaces are tightly regulated by ADAMTS13 through proteolytic cleavage of VWF strings. In the absence or reduction of ADAMTS13 activity, ultra-large von Willebrand factor strings remain anchored at the endothelium and can recruit flowing platelets and causing uncontrolled thrombosis in terminal arterioles and capillaries [20–23]. Along with endothelial inflammation and recruitment of immune competent cells, such deregulation of the ADAMTS13-vWF axis can play a critical role in the pathophysiology of thrombotic complications observed in human B. lanceolatus envenoming.
Our experimental results provide the new information that incubation of human plasma with known elevated ADAMTS13 activities with B. lanceolatus venom dose dependently reduced ADAMTS13 activity. In line, findings in Bothrops sp. envenoming have previously reported mild reduction of ADAMTS13 activity in rodents [26,27]. Such observations have been attributed to the proteolytic cleavage of ADAMTS13 by snake venom metalloproteinases (SVMP), because Na2-EDTA (a SVMP inhibitor) may partially block these alterations [26]. It has been also shown that enzymatic activities of thrombin, FXa, and plasmin, which typically generated in the systemic circulation during Bothrops sp. envenoming, can induced a proteolytic inactivation of ADAMTS13 [33]. Incubation of ADAMTS13 with varying concentrations of human thrombin, followed by Western blotting with the anti-ADAMTS13 protease domain antibody, revealed that ADAMTS13 was cleaved by thrombin in a time- and concentration-dependent fashion. Similarly, experiments performed using FXa and plasmin demonstrated that the factors caused ADAMTS13 fragmentation similarly to that caused by thrombin [33,34]. In addition to proteolytical inactivation [33,34], conformational changes of ADAMTS13, i.e., closed or open, have been consistently shown to alter its activity [35,36]. For example, disruption of the closed conformation of ADAMTS13 contributes to increased ADAMTS13 activity toward VWF [35].
Our clinical study suggests that some patients suffering from B. lanceolatus envenoming displayed moderately low ADAMTS13 activity. According to our results, it was considered that reduced ADAMTS13 activity <75% was not associated with more severe envenoming. However, compared with patients with normal ADAMTS13 activity, those with moderately low ADAMTS13 activity have no major changes in coagulation tests but displayed biological evidence of systemic inflammatory, such as higher fibrinogen and C-reactive protein levels. An increased risk of thrombosis is expected in patients with moderately low ADAMTS13 activity due to the imbalance of the ADAMTS13/VWF axis (decreased levels of ADAMTS13 and increased levels of VWF multimers), which exacerbates the thromboinflammatory response and in turn causes hypercoagulation, inhibition of fibrinolysis, neutrophil activation, and interaction with neutrophil extracellular traps [37–40]. Hence, it is proposed that reduced ADAMTS13 activity observed in some B. lanceolatus envenomed patients can be associated with an increased risk of thrombotic events.
New information provided by our study emphasizes prognosis factors that may independently and collectively pose a risk to B. lanceolatus envenoming patients [41,42]. Previously published risk factors of increased hospital stays and poor outcome in adults include delay from the bite to adequate antivenom therapy, acute renal failure and abnormal blood results such as thrombocytopenia, coagulation test derangements (prothrombin time > 13.2 s, partial thromboplastin time > 37.2 s, low fibrinogen levels), elevated creatinine kinase (CK), along with organ failure (respiratory failure, shock, neurotoxicity, ischemic stroke) associated with specific snake species [43–45]. Several scoring systems have been developed to risk-stratify patients with snakebite envenoming. The Snakebite Severity Score is an objective symptom severity scoring tool developed and validated for the evaluation of initial severity and crotaline envenomation progression and to guide antivenom therapy [44]. This score provides a comprehensive framework based on clinical assessment and coagulation tests to facilitate risk stratification of envenoming [43–45]. In our experience in Martinique, we used a simple scale to grade patients bitten by B. lanceolatus, which focuses on signs such as swelling, pain, and systemic manifestations [41,42]. Minor presentations on this scale are grade 1, while severe swelling with or without systemic features is assigned to grade from 2 to 4 guide decision and dose for antivenom [6,39,40].
In the present study, the number of thrombotic events, which may be mechanistically related to low ADAMTS13 levels, was quite low. Such a small sample size (n = 2) precluded any consistent analysis aimed to identify low ADAMTS13 levels as an independent predictor of thrombotic events in patients suffering B. lanceolatus envenoming. Because low ADAMTS13 levels has been consistently associated with end-organ failure, longer hospital stays and increased mortality in various pathologies [24,25,46–48], we investigated whether low ADAMTS13 level was an independent predictor increased length of hospital stay. The present study confirms that the grading severity system used in Martinique was an independent predictor of length of hospital stay, while reduced ADAMTS13 activity and increased C-reactive protein levels bordered on statistical significance. Of note, advanced age is one of the main factors affecting the levels of many biological parameters. In our series, patients with reduced ADAMTS13 activity were older than those with normal activity. Hence, age (≥65-year-old) could have contributed to aberrant plasma indicators of endothelial coagulopathy such as ADAMTS13 [49]. Hence, while normal levels of biological markers for a healthy elderly people should be considered, no difference was found between patients <65-year-old and patients <65-year-old in our study, suggesting that reduced levels of biomarkers including ADAMTS13 was because of the snake venom, but not related to advanced age.
Limitations of the study
Several study limitations are to be noted in our exploratory research. Few reports have previously provided range of plasmatic venom concentration in B. lanceolatus envenoming. In our in vitro experimental studies, we have used venom concentration in the range of 10–1000 ng/mL, which is in line with those previous observations [39]. Of note, our in vitro experiments clearly suggest that reduced ADAMTS13 activity was a unique feature of B. lanceolatus venom.
One significant concern pertains to the data collection process in this retrospective series of patients hospitalized at the University Hospital of Martinique. All data obtained in the present study was subject to review by the healthcare professionals of the snakebite group at the University Hospital of Martinique responsible for recording clinical information. Another main limitation is the small sample size of our study. Hence, the clinical consequences of reduced ADAMTS13 activity in B. lanceolatus envenoming was not studied in term of thrombosis.
In this series of patients, specific outcome related to ischemic events, i.e., stroke, was not considered since only two cases of stroke were recorded. This issue represents a major concern because one of the main clinical complications of B. lanceolatus envenoming are thrombotic events in the course of the hospitalization. While reduced ADAMTS13 activity has been consistently linked to increased thrombosis risk, our study did not demonstrate a higher incidence of thrombotic events in patients with reduced ADAMTS13.
Regarding the mechanisms of ADAMTS13 reduction, biological testing to document microangiopathic hemolytic anemia was not performed in our study. In our experience in Martinique, this specific complication is not observed in the case of B. lanceolatus envenoming. Typically, envenomed patients presented with normal hemoglobin concentration, normal renal function and absence of schistocytes on the automatized microscopic examination of peripheral blood smear. When considering length of hospital stay as an outcome, our results identified envenoming severity as an independent predictor, but reduced ADAMTS13 activity only bordered on statistical significance in the multivariate linear regression, possibly due to the small sample size of our study. In line with the reduced ADAMTS13 activity, determination of the level of plasmatic ultra-large von Willebrand multimer (ULVWF) was not available in this retrospective study. Indeed, increased ULVWF in the plasma as a consequence of would ascertain the prothrombotic role of reduced ADAMTS13 activity in B. lanceolatus envenoming.
Eventually, whether reduced ADAMTS13 activity is a specific feature of B. lanceolatus venom should be documented in humans by comparison with Bothrops sp. envenoming typically associated with consumption coagulopathy.
Conclusion
For the first time, our study provided evidence suggesting that ADAMTS13 activity is reduced in experimental venom exposure and in human B. lanceolatus envenoming. Such moderately low ADAMTS13 activity may be implicated in the increased risk of thrombosis B. lanceolatus envenomed patients due to the imbalance of the ADAMTS13/VWF axis, which exacerbates biological features of thromboinflammation. Our study results further suggest that, together with high grade severity score of envenoming and increased C-reactive protein, moderately reduced levels of ADAMTS13 activity are associated with increased length of hospital stays.
Supporting information
S1 Table. Levels of main biological parameters of the 46 patients according to age of the patients.
https://doi.org/10.1371/journal.pntd.0013678.s001
(DOCX)
Acknowledgments
The authors declare that generative AI and/or AI-assisted technologies have not been used in the writing process.
References
- 1. Gutiérrez JM, Calvete JJ, Habib AG, Harrison RA, Williams DJ, Warrell DA. Snakebite envenoming. Nat Rev Dis Primers. 2017;3:17079. pmid:28980622
- 2. Seifert SA, Armitage JO, Sanchez EE. Snake Envenomation. N Engl J Med. 2022;386(1):68–78. pmid:34986287
- 3. Monteiro WM, Contreras-Bernal JC, Bisneto PF, Sachett J, Mendonça da Silva I, Lacerda M, et al. Bothrops atrox, the most important snake involved in human envenomings in the amazon: How venomics contributes to the knowledge of snake biology and clinical toxinology. Toxicon X. 2020;6:100037. pmid:32550592
- 4. Resiere D, Kallel H, Florentin J, Houcke S, Mehdaoui H, Gutiérrez JM, et al. Bothrops (Fer-de-lance) snakebites in the French departments of the Americas (Martinique and Guyana): Clinical and experimental studies and treatment by immunotherapy. PLoS Negl Trop Dis. 2023;17(2):e0011083. pmid:36854042
- 5. Resiere D, Hossein M, Megarbane B. Snake Bites by Bothrops lanceolatus in Martinique. Med Sante Trop. 2018;28(1):37–43. pmid:29616641
- 6. Resiere D, Mégarbane B, Valentino R, Mehdaoui H, Thomas L. Bothrops lanceolatus bites: guidelines for severity assessment and emergent management. Toxins (Basel). 2010;2(1):163–73. pmid:22069552
- 7. Thomas L, Chausson N, Uzan J, Kaidomar S, Vignes R, Plumelle Y, et al. Thrombotic stroke following snake bites by the “Fer-de-Lance”Bothrops lanceolatus in Martinique despite antivenom treatment: a report of three recent cases. Toxicon. 2006;48(1):23–8. pmid:16750232
- 8. Thomas L, Tyburn B, Lang J, Ketterle J. Early infusion of a purified monospecific F(ab’)2 antivenom serum for Bothrops lanceolatus bites in Martinique. Lancet. 1996;347(8998):406. pmid:8598738
- 9. Thomas L, Tyburn B, Bucher B, Pecout F, Ketterle J, Rieux D, et al. Prevention of thromboses in human patients with Bothrops lanceolatus envenoming in Martinique: failure of anticoagulants and efficacy of a monospecific antivenom. Research Group on Snake Bites in Martinique. Am J Trop Med Hyg. 1995;52(5):419–26. pmid:7771608
- 10. Resiere D, Kallel H, Florentin J, Houcke S, Mehdaoui H, Gutiérrez JM, et al. Bothrops (Fer-de-lance) snakebites in the French departments of the Americas (Martinique and Guyana): Clinical and experimental studies and treatment by immunotherapy. PLoS Negl Trop Dis. 2023;17(2):e0011083. pmid:36854042
- 11. Resiere D, Florentin J, Mehdaoui H, Kallel H, Legris-Allusson V, Gueye P, et al. Bothrops lanceolatus Envenoming in Martinique: A Historical Perspective of the Clinical Effectiveness of Bothrofav Antivenom Treatment. Toxins (Basel). 2024;16(3):146. pmid:38535812
- 12. Rucavado A, Camacho E, Escalante T, Lomonte B, Fernández J, Solano D, et al. A murine experimental model of the pulmonary thrombotic effect induced by the venom of the snake Bothrops lanceolatus. PLoS Negl Trop Dis. 2024;18(10):e0012335. pmid:39356725
- 13. Radouani F, Jalta P, Rapon C, Lezin C, Branford C, Florentin J, et al. The Contrasting Effects of Bothrops lanceolatus and Bothrops atrox Venom on Procoagulant Activity and Thrombus Stability under Blood Flow Conditions. Toxins (Basel). 2024;16(9):400. pmid:39330858
- 14. Larréché S, Chippaux J-P, Chevillard L, Mathé S, Résière D, Siguret V, et al. Bleeding and Thrombosis: Insights into Pathophysiology of Bothrops Venom-Related Hemostasis Disorders. Int J Mol Sci. 2021;22(17):9643. pmid:34502548
- 15. Noutsos T, Currie BJ, Wijewickrama ES, Isbister GK. Snakebite Associated Thrombotic Microangiopathy and Recommendations for Clinical Practice. Toxins (Basel). 2022;14(1):57. pmid:35051033
- 16. Noutsos T, Isbister GK. Snakebite-associated thrombotic microangiopathy: a spotlight on pharmaceutical interventions. Expert Rev Clin Pharmacol. 2023;16(6):559–74. pmid:37259708
- 17. Malaque CMS, Duayer IF, Santoro ML. Acute kidney injury induced by thrombotic microangiopathy in two cases of Bothrops envenomation. Clin Toxicol (Phila). 2019;57(3):213–6. pmid:30430871
- 18. Bucaretchi F, Pimenta MMB, Borrasca-Fernandes CF, Prado CC, Capitani EMD, Hyslop S. Thrombotic microangiopathy following Bothrops jararaca snakebite: case report. Clin Toxicol (Phila). 2019;57(4):294–9. pmid:30444155
- 19. Mota SMB, Albuquerque PLMM, Silva Júnior GB, Daher EDF. Thrombotic microangiopathy due to Bothrops erythromelas: a case report in Northeast Brazil. Rev Inst Med Trop Sao Paulo. 2020;62:e53. pmid:32725056
- 20. Hanna R, Gibney R, Boysen-Osborn M. Thrombotic Microangiopathies. Emerg Med Clin North Am. 2025;43(3):407–20. pmid:40610058
- 21. Zhou Y, Moake J, Dong J-F. Molecular basis of thrombotic microangiopathy. J Thromb Haemost. 2025;23(10):3019–32. pmid:40541812
- 22. Azoulay E, Veyradier A, Cataland S, Joly BS, Knoebl P, Zafrani L, et al. Thrombotic thrombocytopenic purpura: early diagnosis and effective treatment in 2025. Intensive Care Med. 2025;51(7):1225–39. pmid:40608084
- 23. Deshpande SR, Tarawneh H, Deitelzweig C, Tong J, Zhou T, Chen Y, et al. Rapid ADAMTS13 activity assays for thrombotic thrombocytopenic purpura: a systematic review and meta-analysis. Blood. 2025;146(2):233–46. pmid:40258188
- 24. Sonneveld MAH, de Maat MPM, Portegies MLP, Kavousi M, Hofman A, Turecek PL, et al. Low ADAMTS13 activity is associated with an increased risk of ischemic stroke. Blood. 2015;126(25):2739–46. pmid:26511134
- 25. Sonneveld MAH, Kavousi M, Ikram MA, Hofman A, Rueda Ochoa OL, Turecek PL, et al. Low ADAMTS-13 activity and the risk of coronary heart disease - a prospective cohort study: the Rotterdam Study. J Thromb Haemost. 2016;14(11):2114–20. pmid:27559008
- 26. Thomazini CM, Sachetto ATA, de Albuquerque CZ, de Moura Mattaraia VG, de Oliveira AK, Serrano SM de T, et al. Involvement of von Willebrand factor and botrocetin in the thrombocytopenia induced by Bothrops jararaca snake venom. PLoS Negl Trop Dis. 2021;15(9):e0009715. pmid:34478462
- 27. Larréché S, Chevillard L, Jourdi G, Mathé S, Servonnet A, Joly BS, et al. Bothrops venom-induced hemostasis disorders in the rat: Between Scylla and Charybdis. PLoS Negl Trop Dis. 2023;17(11):e0011786. pmid:38011218
- 28. Sachetto ATA, Jensen JR, Santoro ML. Liver gene regulation of hemostasis-related factors is altered by experimental snake envenomation in mice. PLoS Negl Trop Dis. 2020;14(6):e0008379. pmid:32479494
- 29. Ho WK, Verner E, Dauer R, Duggan J. ADAMTS-13 activity, microangiopathic haemolytic anaemia and thrombocytopenia following snake bite envenomation. Pathology. 2010;42(2):200–2. pmid:20085531
- 30. Casamento AJ, Isbister GK. Thrombotic microangiopathy in two tiger snake envenomations. Anaesth Intensive Care. 2011;39(6):1124–7. pmid:22165369
- 31. Fuchs J, Faber K, Tuchscherer DT, Tsakiris DA, Weiler S, Hofer KE. Bite by a juvenile Bothrops venezuelensis (Venezuelan lancehead) resulting in severe envenomation: A case report. Toxicon. 2020;180:39–42. pmid:32289355
- 32. Malbranque S, Piercecchi-Marti MD, Thomas L, Barbey C, Courcier D, Bucher B, et al. Fatal diffuse thrombotic microangiopathy after a bite by the “Fer-de-Lance” pit viper (Bothrops lanceolatus) of Martinique. Am J Trop Med Hyg. 2008;78(6):856–61. pmid:18541759
- 33. Crawley JTB, Lam JK, Rance JB, Mollica LR, O’Donnell JS, Lane DA. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood. 2005;105(3):1085–93. pmid:15388580
- 34. Shin Y, Miyake H, Togashi K, Hiratsuka R, Endou-Ohnishi K, Imamura Y. Proteolytic inactivation of ADAMTS13 by plasmin in human plasma: risk of thrombotic thrombocytopenic purpura. J Biochem. 2018;163(5):381–9. pmid:29228282
- 35. Bonnez Q, Vanhoorelbeke K. Open or closed? Understanding the molecular mechanisms and clinical implications of ADAMTS13’s conformation. Hemasphere. 2025;9(7):e70189. pmid:40718105
- 36. DeYoung V, Singh K, Kretz CA. Mechanisms of ADAMTS13 regulation. J Thromb Haemost. 2022;20(12):2722–32. pmid:36074019
- 37. Luka N, South K, Jones R, Unsworth AJ, Coutts G, Mosneag I-E, et al. The Role of the VWF/ADAMTS13 Axis in the Thromboinflammatory Response in Ischemic Stroke After SARS-CoV2 Infection. Brain Behav. 2025;15(2):e70348. pmid:39972966
- 38. Kawecki C, Lenting PJ, Denis CV. von Willebrand factor and inflammation. J Thromb Haemost. 2017;15(7):1285–94. pmid:28671350
- 39. Peyvandi F, Garagiola I, Baronciani L. Role of von Willebrand factor in the haemostasis. Blood Transfus. 2011;9 Suppl 2(Suppl 2):s3-8. pmid:21839029
- 40. Gragnano F, Sperlongano S, Golia E, Natale F, Bianchi R, Crisci M, et al. The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy. Mediators Inflamm. 2017;2017:5620314. pmid:28634421
- 41. Bucher B, Canonge D, Thomas L, Tyburn B, Robbe-Vincent A, Choumet V, et al. Clinical indicators of envenoming and serum levels of venom antigens in patients bitten by Bothrops lanceolatus in Martinique. Research Group on Snake Bites in Martinique. Trans R Soc Trop Med Hyg. 1997;91(2):186–90. pmid:9196765
- 42. Thomas L, Tyburn B, Ketterlé J, Biao T, Mehdaoui H, Moravie V, et al. Prognostic significance of clinical grading of patients envenomed by Bothrops lanceolatus in Martinique. Members of the Research Group on Snake Bite in Martinique. Trans R Soc Trop Med Hyg. 1998;92(5):542–5. pmid:9861375
- 43. Wood D. Clinical Risk Factors Associated with Poor Outcomes in Snake Envenoming: A Narrative Review. Toxins (Basel). 2023;15(12):675. pmid:38133179
- 44. Dart RC, Hurlbut KM, Garcia R, Boren J. Validation of a severity score for the assessment of crotalid snakebite. Ann Emerg Med. 1996;27(3):321–6. pmid:8599491
- 45. Fowler AL, Hughes DW, Muir MT, VanWert EM, Gamboa CD, Myers JG. Resource Utilization After Snakebite Severity Score Implementation into Treatment Algorithm of Crotaline Bite. J Emerg Med. 2017; 53:854–61.
- 46. Xu X, Feng Y, Jia Y, Zhang X, Li L, Bai X, et al. Prognostic value of von Willebrand factor and ADAMTS13 in patients with COVID-19: A systematic review and meta-analysis. Thromb Res. 2022;218:83–98. pmid:36027630
- 47. Azfar MF, Khan MF, Habib SS, Aseri ZA, Zubaidi AM, Aguila DO, et al. Prognostic value of ADAMTS13 in patients with severe sepsis and septic shock. Clin Invest Med. 2017;40(2):E49–58. pmid:28447577
- 48. Oh J, Oh D, Lee SJ, Kim JO, Kim NK, Chong SY, et al. Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura. Blood Res. 2019;54(3):218–28. pmid:31730685
- 49. Thangaraju K, Katneni U, Akpan IJ, Tanaka K, Thomas T, Setua S, et al. The Impact of Age and BMI on the VWF/ADAMTS13 Axis and Simultaneous Thrombin and Plasmin Generation in Hospitalized COVID-19 Patients. Front Med (Lausanne). 2022;8:817305. pmid:35087853